Theriva Biologics
TOVX
21 hedge funds and large institutions have $1.3M invested in Theriva Biologics in 2019 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 2 reducing their positions, and 6 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 2
0.04% less ownership
Funds ownership: 0.09% → 0.05% (-0.04%)
9% less funds holding
Funds holding: 23 → 21 (-2)
19% less capital invested
Capital invested by funds: $1.61M → $1.3M (-$313K)
33% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
+$54.2K |
| 2 |
Renaissance Technologies
New York
|
+$33.8K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$12.4K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$10.8K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$8.12K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$312K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$287K |
| 3 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$88K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$13.1K |
| 5 |
Two Sigma Investments
New York
|
-$6K |
TOVX Hedge Fund Activity: Q1 2019 in Review
21 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Theriva Biologics (TOVX) for Q1 2019, worth a combined $1.3M — down 19% from $1.61M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of TOVX and 4 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 6 added.
The largest buyer was Virtu Financial, adding an estimated $54.2K. The largest seller was Armistice Capital, exiting entirely with an estimated $312K sold.
- 21 institutional investors held Theriva Biologics (TOVX) as of Q1 2019, down from 23 in Q4 2018.
- Funds reported $1.3M of Theriva Biologics stock for Q1 2019, down 19% quarter-over-quarter.
- 4 funds opened new Theriva Biologics positions in Q1 2019 and 6 closed out, a net change of -2 holders.
- The largest Theriva Biologics buyer in Q1 2019 was Virtu Financial, an estimated $54.2K added.
- The largest Theriva Biologics seller in Q1 2019 was Armistice Capital, an estimated $312K sold.
Based on aggregated 13F filings for Q1 2019.